Revenue
2023
2024
Aktis Oncology, Inc. (AKTS)
Price—Loading quote
Net income
2023
2024
Free cash flow
2023
2024
Total cash / debt
CashTotal debt
2023
2024
Financial statements
| 2024 | 2023 | |
|---|---|---|
| Revenue | $1.5M | $0 |
| Research & development | $41.0M | $25.9M |
| Operating income | −$52.0M | −$34.8M |
| EBITDAderived | −$50.5M | −$33.7M |
| Net income | −$44.0M | −$28.6M |
| Diluted EPSper diluted share | -$62.46 | -$46.56 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jan 12, 2026Form 4 | Foley ToddDirector,TenPercentOwner | BuyCommon Stock · indirect | 232.9K | $18.00 | $4.19M | 4.24M |
| Jan 12, 2026Form 4 | MPM ONCOLOGY INNOVATIONS FUND LP +7TenPercentOwner | BuyCommon Stock · indirect | 1.11M | $18.00 | $20.03M | 10.26M |
| Jan 12, 2026Form 4 | GADICKE ANSBERT +2TenPercentOwner | BuyCommon Stock · indirect | 1.11M | $18.00 | $20.03M | 10.26M |
| Jan 12, 2026Form 4 | VIDA VENTURES II-A, LLC +1TenPercentOwner | BuyCommon Stock · indirect | 22.5K | $18.00 | $405.8K | 157.4K |
| Jan 12, 2026Form 4 | VIDA VENTURES II-A, LLC +1TenPercentOwner | BuyCommon Stock · indirect | 812.5K | $18.00 | $14.62M | 5.67M |